Pharma Marketing Network

APRIL 21, 2025

Introduction In the ever-evolving world of healthcare promotion, pharma brands are constantly seeking reliable, cost-effective, and targeted strategies to stay connected with healthcare professionals (HCPs) and patients. Enter email marketing campaigns a digital tactic that’s proving to be more than just effective. But are these campaigns truly worth the investment in 2025’s competitive and compliance-heavy landscape?

HIPAA 52

HIPAA Communication Diabetes 52

STAT

APRIL 23, 2025

Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of engaging in the corporate practice of medicine. To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as

Compounding 356

Compounding Compounding Pharmacies Diabetes 356

PharmaVoice

APRIL 22, 2025

The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

342

342

European Pharmaceutical Review

APRIL 22, 2025

New Phase III data has demonstrated the potential benefit of the monoclonal antibody obinutuzumab to treat lupus nephritis. This therapy is already approved for B cell malignancies. The REGENCY Phase III clinical trial evaluated 271 adults with active lupus nephritis, a severe complication of lupus that inhibits kidney function. Participants were randomised to receive either obinutuzumab plus mycophenolate mofetil and glucocorticoids as standard therapy, or a placebo plus standard therapy.

111

111

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

Express Pharma

APRIL 23, 2025

Indias pharma and healthcare sector recorded 71 deals amounting to USD 2.6 billion in Q1 2025, according to the Grant Thornton Bharat Pharma & Healthcare Dealtracker. While this marks a 5 per cent decline in deal volume and a 69 per cent drop in deal value compared to Q4 2024, the report notes continued investor interest. Mergers and acquisitions (M&A) accounted for 57 per cent of the total deal value, while private equity (PE) made up 59 per cent of the overall deal volume.

Hospitals 87

Hospitals 87

PharmaVoice

APRIL 25, 2025

A look at the government’s far-reaching rollback in research grants so far.

245

245

European Pharmaceutical Review

APRIL 21, 2025

For the first time in over ten years, the US Food and Drug Administration (FDA) has approved a new targeted treatment for chronic spontaneous urticaria. Sanofi and Regeneron Pharmaceuticals collaborated to develop Dupixent (dupilumab). Under the FDA’s new authorisation, the therapy is indicated for individuals aged 12 years and over with the chronic inflammatory skin disease, who still experience symptoms despite taking histamine-1 (H1) antihistamine medication.

105

105

The Pharmacist

APRIL 23, 2025

The Royal Pharmaceutical Society (RPS) is recruiting for a new director for England after previous postholder Dr James Davies left the role at the end of last year. Applicants for the 80,000-85,000 director for England role must be a pharmacist, an RPS member, and have experience or knowledge of more than one sector in pharmacy […] The post New leadership role created at RPS as director for England sought appeared first on The Pharmacist.

87

87

STAT

APRIL 22, 2025

Imagine a clinical trial with sedentary, overweight adults. One group is assigned to remain sedentary, the other to undergo intensive physical training with daily runs, calisthenics, and sports. After a week or two, the training group would probably feel sore and tired, and their endurance might be reduced. But we wouldn’t conclude that physical activity is bad for health.

361

361

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

PharmaVoice

APRIL 21, 2025

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

221

221

Drug Patent Watch

APRIL 23, 2025

"Patent Expiration: The $1.4 Trillion Wake-Up Call for the Pharmaceutical Industry As the pharmaceutical landscape continues to shift, one thing is clear: the expiration of drug patents is no longer a footnote in the industry's financials. According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.

84

84

Express Pharma

APRIL 24, 2025

Morepen Laboratories has announced the launch of four new productsTicapen, UdoFix, LycoMore, and Acifix Raftin April 2025 for the Indian market. This follows the introduction of Empamore last month, furthering the companys stated goal to offer research-led pharmaceutical products across key therapeutic areas. These launches form part of Morepens broader strategy to enhance its finished dosages segment while leveraging its internal research and development (R&D) capabilities.

Packaging 85

Packaging Dosage Immunity Immunization 85

STAT

APRIL 21, 2025

High blood pressure earned its reputation as the silent killer by causing heart attacks, heart failure, and strokes. It’s also been a suspect in dementia. Some studies have hinted at a correlation between lower blood pressure and fewer dementia cases, but they were too small and too short to lend statistical significance to the link. It’s also been noted that people with untreated high blood pressure carry a 42% higher risk of developing dementia.

348

348

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

PharmaVoice

APRIL 21, 2025

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

182

182

The Pharmacist

APRIL 24, 2025

The government has launched a call for evidence to support its Mens Health Strategy, which was announced last year and is the first of its kind. Health professionals are among those being asked for ideas and evidence to the unique challenges men face throughout their lives. The strategyis being developed to tackle stark inequalities in […] The post Government seeks pharmacists' views to underpin first-ever mens health strategy appeared first on The Pharmacist.

80

80

Express Pharma

APRIL 24, 2025

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tolvaptan Tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. The approved product is bioequivalent to Jynarque Tablets of the same strengths, originally developed by Otsuka Pharmaceutical Company Lupin is the exclusive first-to-file applicant for this product, making it eligible for 180 days of generic drug exclusivity in the United States.

Pharmaceutical Companies 89

Pharmaceutical Companies Pharmaceutical Companies 89

STAT

APRIL 24, 2025

Some key public health figures are taking an extraordinary step to try to shore up U.S. vaccination policy, feared to be under threat from Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine critic. The “Vaccine Integrity Project,” which was publicly launched Thursday by the University of Minnesota’s Center for Infectious Disease Research and Policy, will be aimed at assessing the best ways for vaccine proponents to safeguard vaccination policy and

Vaccines 333

Vaccines 333

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmafile

APRIL 25, 2025

Vect-Horus has announced the appointment of Philippe Masset to the companys board of directors. This contributes to a series of senior leadership appointments which are strategic for Vect-Horus growth. Masset is a senior banking executive with a wealth of experience in investment banking, environmental, social and governance (ESG) topics, sustainable finance, and AI.

76

76

FDA Law Blog: Biosimilars

APRIL 21, 2025

By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a

Documentation 64

Documentation Drug Development 64

PharmaVoice

APRIL 24, 2025

A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

162

162

STAT

APRIL 24, 2025

The federal health department is not creating a new registry of Americans with autism, a Department of Health and Human Services official said in a written statement Thursday. Instead, the official said, HHS will launch a $50 million research effort to understand the causes of autism spectrum disorder and improve treatments. The announcement arrives two days after National Institutes of Health Director Jay Bhattacharya announced the intent to create such a registry at an all staff meeting, kicki

363

363

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmafile

APRIL 22, 2025

Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been appointed founding CEO of the newly created subsidiary, currently named SpinCo. The subsidiary, which will operate independently following the split, is funded by Galapagos. Gosebruch joins SpinCo with extensive experience in business development and mergers […] The post Galapagos announces leadership changes amid planned company split appeared first on Pharm

64

64

The Pharmacist

APRIL 25, 2025

Almost five million Pharmacy First consultations were delivered in the first year of the service in England, official data has confirmed. The latest data from the NHS Business Services Authority (NHSBSA) shows that contractors in England submitted claims for 4,941,308 Pharmacy First consultations between February 2024 and January 2025. Of those, more than half (2,735,577) […] The post Almost five million Pharmacy First consultations delivered in first year appeared first on The Pharmacist.

59

59

Express Pharma

APRIL 25, 2025

ENTOD Pharmaceuticals has announced that it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for a new ophthalmic formulation designed to slow the progression of myopia in children aged 6 to 12 years. This marks the first global regulatory approval for this specific treatment strength in paediatric eye care.

59

59

STAT

APRIL 23, 2025

The young people who wanted to quit e-cigarettes didn’t necessarily think they were addicted. But they did think nicotine cravings were a problem. When they enrolled in a Massachusetts General Hospital trial, they told researchers they couldn’t study in the library or work at their desks for long before getting the urge to vape. “They really didn’t like that loss of control,” said Eden Evins, director of the addiction center at Mass General.

Hospitals 258

Hospitals 258

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Drug Channels

APRIL 23, 2025

Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , we explore how pharmaceutical manufacturers structure their specialty pharmacy networksand how smaller, independent pharmacies have emerged as dominant pl

Specialty Pharmacies 72

Specialty Pharmacies Independent Pharmacies Pharmaceutical Manufacturing 72

Pharmafile

APRIL 23, 2025

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), and recommended by the National Institute for Health and Care Excellence (NICE). It is now a treatment option via NHS-funded commissioning, marking a major milestone for treating patients with […] The post Dual immunotherapy for bowel cancer now available under NHS appeared first on Pharmafile.

66

66

Express Pharma

APRIL 22, 2025

As monoclonal antibody (mAb) therapies and biosimilars reshape the global biologics landscape with the mAbs market expected to grow from USD 233.19 billion in 2024 to reach around USD 919.06 billion by 2033 [1] Cytiva announced the launch of two advanced protein A chromatography resins: MabSelect SuRe 70 and MabSelect PrismA X. Developed to meet the evolving purification demands of biopharma innovators, these next-generation resins deliver enhanced productivity, durability, and affordability ac

Biosimilars 66

Biosimilars Drug Development 66